Abbott Finalizes Purchase of Exact Sciences to Expand Cancer Diagnostics
雅培完成對 Exact Sciences 的收購，旨在擴大癌症診斷業務
On March 23, 2026, healthcare giant Abbott finalized its acquisition of Exact Sciences for $23 billion, a move set to transform the landscape of cancer diagnostics.
2026年3月23日，醫療保健巨頭亞培（Abbott）以230億美元完成了對Exact Sciences的收購，此舉將徹底改變癌症診斷的產業版圖。
By acquiring Exact Sciences, Abbott gains access to advanced technologies like the noninvasive Cologuard test and Oncotype DX genomic tests.
透過收購Exact Sciences，亞培獲得了諸如非侵入性（ㄈㄟ ㄧㄣ ㄖㄨˋ ㄒㄧㄥˋ）Cologuard檢測和Oncotype DX基因檢測等先進技術。
This strategic expansion is designed to make Abbott a leader in the high-growth fields of cancer screening and precision oncology, effectively doubling its addressable market in this sector to over $120 billion.
這項策略性擴張旨在讓亞培成為癌症篩檢與精準腫瘤學（ㄓㄨㄥ ㄌㄧㄡˊ ㄒㄩㄝˊ）高成長領域的領導者，有效將其在該領域的可觸及市場規模翻倍，超過1200億美元。
Financially, the deal is expected to add roughly $3 billion in incremental sales to Abbott’s 2026 performance, pushing total annual diagnostics sales beyond $12 billion.
財務方面，該交易預計將為亞培2026年的績效增加約30億美元的增量銷售額，使年度診斷銷售總額突破120億美元。
Exact Sciences will operate as a subsidiary based in Madison, Wisconsin, with former CEO Kevin Conroy moving into an advisory position.
Exact Sciences將作為位於威斯康辛州麥迪遜市的子公司營運，前執行長Kevin Conroy將轉任顧問職位。
This major transaction highlights Abbott's commitment to shifting its portfolio toward predictive and personalized medicine, solidifying its role at the forefront of modern medical innovation.
這項重大交易凸顯了亞培致力於將產品組合轉向預測性與個人化醫療的決心，鞏固了其站在現代醫療創新最前線的地位。
